Novel Translational Control Mechanisms in Host Range Restriction of Poxvirus
痘病毒宿主范围限制的新型翻译控制机制
基本信息
- 批准号:10463680
- 负责人:
- 金额:$ 42.24万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-22 至 2025-08-31
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
All viruses rely on host translational machinery for protein synthesis. As such, translation
control constitutes a universal host defense against viruses. A new understanding on how host
regulates translation in response to viral infection and how viruses evade this host response will
provide fundamental insight into viral pathogenesis and benefit the development of new antiviral
strategies.
Poxviruses include some dangerous emerging pathogens as well as some promising vaccine
vectors. Unlike many other viruses, poxvirus host range is not affected by the entry step but
restricted by intracellular processes. Particularly, cellular translational control pathways have a
profound impact on poxvirus host range, and poxvirus inhibitors of these pathways could
manifest as critical host-range factors. The best-known example is PKR-mediated control of
translation initiation and its antagonism by two vaccinia virus (VACV) host-range proteins E3
and K3. Much less is understood about a PKR-independent pathway targeted by two critical
VACV host-range proteins, K1 and C7. VACV with deletion in both K1 and C7 fails to replicate
in most mammalian cells due to a shut-off of viral and host protein synthesis. Intriguingly, the
translational shut-off is independent of PKR and RNaseL and appears not to involve any
translation initiation factors. A paralogous pair of interferon-stimulated genes, SAMD9 and
SAMD9L (SAMD9&L), were recently identified by us and others as the specific targets of K1
and C7. However, how they regulate protein synthesis and restrict poxvirus host range is
unknown and is the focus of this proposal.
We have made sustained contributions to the understanding of K1/C7 and their cellular
targets for over a decade, including the determination of the structures of K1/C7 and the
identification of SAMD9L as a cellular target of K1/C7. In addition, we have obtained compelling
preliminary data that led to our novel hypotheses, which will be addressed separately with the
following specific aims.
Aim 1. To determine how SAMD9 is activated to inhibit protein synthesis.
Aim 2. To determine how activated SAMD9 inhibits protein synthesis.
Aim 3. To determine the molecular basis underlying the host species-specific SAMD9&L
inhibition by OPXV inhibitors.
所有病毒都依靠宿主翻译机制来蛋白质合成。因此,翻译
控制构成了对病毒的普遍防御。对主持人的新理解
根据病毒感染的响应调节翻译,以及病毒如何逃避这种宿主反应
提供对病毒发病机理的基本洞察力,并有益于新抗病毒的发展
策略。
痘病毒包括一些危险的新兴病原体以及一些有希望的疫苗
向量。与许多其他病毒不同,Poxvirus宿主范围不受进入步骤的影响,而是
受细胞内过程的限制。特别是,细胞翻译控制途径具有
对痘病毒宿主范围和这些途径的痘病毒抑制剂的深远影响可能
表现为关键的宿主范围因素。最著名的例子是PKR介导的控制
翻译起始及其拮抗两种离子病毒(VACV)宿主范围蛋白E3的拮抗作用
和K3。关于由两个关键目标针对的独立于PKR的途径所理解的要少得多
VacV宿主范围蛋白K1和C7。 K1和C7中删除删除的VAVV均无法复制
在大多数哺乳动物细胞中,由于病毒和宿主蛋白质合成的关闭而引起的。有趣的是,
翻译关闭与PKR和RNASEL无关,似乎不涉及任何
翻译起始因子。一对寄生的干扰素刺激的基因SAMD9和
SAMD9L(SAMD9&L)最近被美国和其他人确定为K1的特定目标
和C7。但是,它们如何调节蛋白质合成和限制痘病毒宿主范围是
未知,是该提议的重点。
我们为理解K1/C7及其细胞做出了持续的贡献
目标已有十多年了,包括确定K1/C7的结构
将SAMD9L鉴定为K1/C7的细胞靶标。另外,我们获得了引人注目的
初步数据导致了我们的新假设,该假设将与
遵循特定目标。
目的1。确定如何激活SAMD9以抑制蛋白质合成。
目标2。确定活化的SAMD9如何抑制蛋白质的合成。
目标3。确定宿主特异性SAMD9&L的分子基础
OPXV抑制剂抑制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

暂无数据
数据更新时间:2024-06-01
Junpeng Deng的其他基金
Developing small molecule inhibitors for modulating cytokine IL18 activities
开发调节细胞因子 IL18 活性的小分子抑制剂
- 批准号:1039362410393624
- 财政年份:2021
- 资助金额:$ 42.24万$ 42.24万
- 项目类别:
Developing small molecule inhibitors for modulating cytokine IL18 activities
开发调节细胞因子 IL18 活性的小分子抑制剂
- 批准号:1022642010226420
- 财政年份:2021
- 资助金额:$ 42.24万$ 42.24万
- 项目类别:
Structure function studies of a molecular complex for generating viral membrane
用于生成病毒膜的分子复合物的结构功能研究
- 批准号:1017027310170273
- 财政年份:2020
- 资助金额:$ 42.24万$ 42.24万
- 项目类别:
Novel Translational Control Mechanisms in Host Range Restriction of Poxvirus
痘病毒宿主范围限制的新型翻译控制机制
- 批准号:1038208110382081
- 财政年份:2020
- 资助金额:$ 42.24万$ 42.24万
- 项目类别:
Novel Translational Control Mechanisms in Host Range Restriction of Poxvirus
痘病毒宿主范围限制的新型翻译控制机制
- 批准号:1068040810680408
- 财政年份:2020
- 资助金额:$ 42.24万$ 42.24万
- 项目类别:
Novel Translational Control Mechanisms in Host Range Restriction of Poxvirus
痘病毒宿主范围限制的新型翻译控制机制
- 批准号:1067583110675831
- 财政年份:2020
- 资助金额:$ 42.24万$ 42.24万
- 项目类别:
Novel Translational Control Mechanisms in Host Range Restriction of Poxvirus
痘病毒宿主范围限制的新型翻译控制机制
- 批准号:1026777010267770
- 财政年份:2020
- 资助金额:$ 42.24万$ 42.24万
- 项目类别:
Structure function studies of a molecular complex for generating viral membrane
用于生成病毒膜的分子复合物的结构功能研究
- 批准号:1005785210057852
- 财政年份:2020
- 资助金额:$ 42.24万$ 42.24万
- 项目类别:
Non-vesicular lipid transport by poxvirus A6 protein
痘病毒 A6 蛋白的非囊泡脂质转运
- 批准号:93797629379762
- 财政年份:2017
- 资助金额:$ 42.24万$ 42.24万
- 项目类别:
Structure-function studies on a key signaling module from interleukin 17 receptor
白细胞介素17受体关键信号模块的结构-功能研究
- 批准号:87719958771995
- 财政年份:2014
- 资助金额:$ 42.24万$ 42.24万
- 项目类别:
相似国自然基金
DMWD结合LATS1通过负向调控Hippo-YAP信号通路促进恶性胶质瘤干性的分子机制
- 批准号:82302980
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
异戊二烯化修饰Rac3结合PKD2/Arfaptin-2复合体介导MMP1/2囊泡分泌促进头颈鳞癌侵袭转移的机制研究
- 批准号:82303507
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
多组学探究RNA结合蛋白RBM22在5q-综合征中的功能与机制
- 批准号:
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:
结合诱导纤维生成肽长效抑制角膜新生血管形成治疗角膜病的机制
- 批准号:
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:
污水处理系统结合态雌激素的生物转化机制与风险削减研究
- 批准号:52370200
- 批准年份:2023
- 资助金额:51 万元
- 项目类别:面上项目
相似海外基金
Identification of resistance mechanisms to direct KRAS inhibition in pancreatic cancer
鉴定胰腺癌中直接 KRAS 抑制的耐药机制
- 批准号:1057247710572477
- 财政年份:2023
- 资助金额:$ 42.24万$ 42.24万
- 项目类别:
Exploring envelope stress response toxicity and regulation in gram-negative bacteria
探索革兰氏阴性菌的包膜应激反应毒性和调节
- 批准号:1062950510629505
- 财政年份:2023
- 资助金额:$ 42.24万$ 42.24万
- 项目类别:
Investigating the role of the Ccr4-Not complex in regulating codon optimality-mediated mRNA decay
研究 Ccr4-Not 复合体在调节密码子最优性介导的 mRNA 衰减中的作用
- 批准号:1074998510749985
- 财政年份:2023
- 资助金额:$ 42.24万$ 42.24万
- 项目类别:
The Role of mRNA Degradation in Embryonic Cell Fate Specification
mRNA 降解在胚胎细胞命运规范中的作用
- 批准号:1060451210604512
- 财政年份:2023
- 资助金额:$ 42.24万$ 42.24万
- 项目类别:
Role of Heat Shock Protein 70 as a Mediator and Therapeutic Target in T-cell Lymphomas
热休克蛋白 70 作为 T 细胞淋巴瘤介质和治疗靶点的作用
- 批准号:1066922110669221
- 财政年份:2022
- 资助金额:$ 42.24万$ 42.24万
- 项目类别: